TAXIS Pharmaceuticals Announces $2.67 Million NIH Grant to Advance Research and Development of Combination Therapy to Combat Antibiotic-Resistant Pneumonia
TAXIS Pharmaceuticals announces CARB-X award of $3.2 million, with potential for an additional $11.4 million, to develop Efflux Pump Inhibitors (EPIs), a new drug class to defeat multi-drug resistant infections
TAXIS Pharmaceuticals to Present Pipeline Update at Biotech in Europe Forum: President and CEO Gregory Mario to Highlight Progress in Antibiotic Drug Development Focusing on Efflux Pump Inhibition and Modulation of FtsZ and MreB Proteins
FDA Grants Special Designation to TAXIS Pharmaceuticals Experimental Antibiotic: Compound Named a Qualified Infectious Disease Product (QIDP) for Acute Bacterial Skin and Skin Structure Infections
TAXIS PHARMACEUTICALS DEMONSTRATES SYNERGISTIC EFFICACY AGAINST MRSA AND LOW RESISTANCE FREQUENCY WITH TXA709/CEFDINIR COMBINATION: Poster Presentation at ICAAC 2015 Highlights Potential of TXA709, Both Alone and in Combination with Cefdinir, as Oral Antibiotic for Drug-Resistant S. aureus Infections
TAXIS PHARMACEUTICALS DEMONSTRATES CLINICAL POTENTIAL OF TXA709 IN COMBATING ANTIBIOTIC RESISTANCE: Poster Presentation at ECCMID 2015 Highlights Unique Mechanism of Action and Potent Bactericidal Activity against MRSA Strains
